IMITINIB DRUG RESISTANT ANALYSIS BY RT PCR AND RESTRICTION ANALYSIS
| Imatinib is a Tyrosine kinase inhibitor (TKI) capable of inducing durable hematologic and cytologic remissions in patients with Chronic Myeloid Leukemia (CML). Unfortunately a significant subset of patients develop functional resistance to TKI. Recognition of this resistance is important in CML as the effect of some mutations can be overcome by Imatinib dosage. |
Pre-test Information : Submit latest BCR-ABL Quantitative report along with sample |
|---|
Report Delivery : Daily |
IMITINIB DRUG RESISTANT ANALYSIS BY RT PCR AND RESTRICTION ANALYSIS
| Test Code | I-001 |
|---|---|
| Test Description | **IMITINIB DRUG RESISTANT ANALYSIS BY RT PCR AND RESTRICTION ANALYSIS |
| Clinical Category | THERAPEUTIC DRUG MONITORING |
| Sample | 4 mL Whole blood in EDTA tube |
| Method/Technology | PCR, Sequencing |
| Storage/Temp | |
| Reporting Time |